Gain Therapeutics, Inc.
For the period ended Jun 30, 2025. Filed Aug 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 12, 2025
GANX$1.08-0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Common Stock · · AdditionalPaid-in · · AccumulatedOtherComprehensive · · Accumulated · · · | |||||||||||||||||
| Three Months Ended June 30, 2025 · Shares · Amounts · Capital · Income (Loss) · Deficit · Total | |||||||||||||||||
| Balance as of March 31, 2025 | | 28,746,041 | | $2,875 | | $91,621,667 | | $(119,865) | | $(85,724,966) | | $5,779,711 | |||||
| Stock-based compensation (Note 15) | | 31,210 | | 3 | | 530,496 | | — | | — | | 530,499 | |||||
| Exercise of warrants (Note 14) | | 576,709 | | | 58 | | | — | | | — | | | — | | | 58 |
| Changes in defined benefit pension plan obligation (Note 11) | | — | | — | | — | | 5,934 | | — | | 5,934 | |||||
| Foreign currency translation | | — | | — | | — | | 698,014 | | — | | 698,014 | |||||
| Issuance of shares in at-the-market ("ATM") offering (Note 14) | | 1,417,361 | | | 142 | | | 2,490,779 | | | — | | | — | | | 2,490,921 |
| Net loss | | — | | | — | | | — | | | — | | | (5,809,087) | | | (5,809,087) |
| Balance as of June 30, 2025 | | 30,771,321 | | $3,078 | | $94,642,942 | | $584,083 | | $(91,534,053) | | $3,696,050 | |||||
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Common Stock · · AdditionalPaid-in · · AccumulatedOtherComprehensive · · Accumulated · · · | |||||||||||||||||
| Six Months Ended June 30, 2025 · Shares · Amounts · Capital · Income (Loss) · Deficit · Total | |||||||||||||||||
| Balance as of December 31, 2024 | | 27,132,588 | | $2,713 | | $88,779,318 | | $(247,549) | | $(81,194,908) | | $7,339,574 | |||||
| Stock-based compensation (Note 15) | | 95,069 | | 9 | | 953,635 | | — | | — | | 953,644 | |||||
| Exercise of warrants (Note 14) | | 1,031,602 | | | 105 | | | — | | | — | | | — | | | 105 |
| Changes in defined benefit pension plan obligation (Note 11) | | — | | — | | — | | 10,760 | | — | | 10,760 | |||||
| Foreign currency translation | | — | | — | | — | | 820,872 | | — | | 820,872 | |||||
| Issuance of shares in ATM offering (Note 14) | | 2,512,062 | | | 251 | | | 4,909,989 | | | — | | | — | | | 4,910,240 |
| Net loss | | — | | | — | | | — | | | — | | | (10,339,145) | | | (10,339,145) |
| Balance as of June 30, 2025 | | 30,771,321 | | $3,078 | | $94,642,942 | | $584,083 | | $(91,534,053) | | $3,696,050 | |||||
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Common Stock · · AdditionalPaid-in · · Accumulated Other Comprehensive · · Accumulated · · · | |||||||||||||||||
| Three Months Ended June 30, 2024 · · Shares · · Amounts · · Capital · · Income (Loss) · · Deficit · · Total | |||||||||||||||||
| Balance as of March 31, 2024 | | 18,041,231 | | $1,805 | | $73,416,304 | | $21,863 | | $(64,797,911) | | $8,642,061 | |||||
| Stock-based compensation (Note 15) | | 4,858 | | — | | 1,432,859 | | — | | — | | 1,432,859 | |||||
| Exercise of warrants (Note 14) | | 9,937 | | | 1 | | | 13,575 | | | — | | | — | | | 13,576 |
| Defined benefit pension plan adjustments (Note 11) | | — | | — | | — | | 1,090 | | — | | 1,090 | |||||
| Foreign currency translation | | — | | — | | — | | (11,137) | | — | | (11,137) | |||||
| Net unrealized gain on available-for-sale securities (Note 5) | | — | | | — | | | — | | | 646 | | | — | | | 646 |
| Issuance of shares and warrants in public offering (Note 14) | | 7,116,547 | | | 712 | | | 9,848,009 | | | — | | | — | | | 9,848,721 |
| Net loss | | — | | | — | | | — | | | — | | | (8,143,078) | | | (8,143,078) |
| Balance as of June 30, 2024 | | 25,172,573 | | $2,518 | | $84,710,747 | | $12,462 | | $(72,940,989) | | $11,784,738 | |||||
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Common Stock · · AdditionalPaid-in · · Accumulated Other Comprehensive · · Accumulated · · · | |||||||||||||||||
| Six Months Ended June 30, 2024 · · Shares · · Amounts · · Capital · · Income (Loss) · · Deficit · · Total | |||||||||||||||||
| Balance as of December 31, 2023 | | 16,206,680 | | $1,621 | | $73,113,079 | | $247,241 | | $(60,783,717) | | $12,578,224 | |||||
| Stock-based compensation (Note 15) | | 35,983 | | 3 | | 1,578,329 | | — | | — | | 1,578,332 | |||||
| Exercise of stock options (Note 15) | | 15,983 | | | 2 | | | 57,709 | | | — | | | — | | | 57,711 |
| Exercise of warrants (Note 14) | | 1,797,380 | | | 180 | | | 113,621 | | | — | | | — | | | 113,801 |
| Defined benefit pension plan adjustments (Note 11) | | — | | — | | — | | 2,176 | | — | | 2,176 | |||||
| Foreign currency translation | | — | | — | | — | | (241,929) | | — | | (241,929) | |||||
| Net unrealized gain on available-for-sale securities (Note 5) | | — | | | — | | | — | | | 4,974 | | | — | | | 4,974 |
| Issuance of shares and warrants in public offering (Note 14) | | 7,116,547 | | | 712 | | | 9,848,009 | | | — | | | — | | | 9,848,721 |
| Net loss | | — | | | — | | | — | | | — | | | (12,157,272) | | | (12,157,272) |
| Balance as of June 30, 2024 | | 25,172,573 | | $2,518 | | $84,710,747 | | $12,462 | | $(72,940,989) | | $11,784,738 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.